Predicted mechanisms of resistance to mTOR inhibitors

Research output: Contribution to journalShort survey

82 Scopus citations

Abstract

The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.

Original languageEnglish (US)
Pages (from-to)955-960
Number of pages6
JournalBritish Journal of Cancer
Volume95
Issue number8
DOIs
StatePublished - Oct 23 2006
Externally publishedYes

    Fingerprint

Keywords

  • Cap-dependent translation
  • Clinical resistance
  • Kinase inhibitors
  • Mammalian target of rapamycin (mTOR)
  • Rapamycin
  • Resistance mechanisms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this